HRT With a History of Endometriosis: What Every Woman Needs to Know

Why Endometriosis History Changes the HRT Conversation

Endometriosis affects roughly 10% of reproductive-age women worldwide, and a significant fraction of those women will eventually need menopausal hormone therapy. The European Society of Human Reproduction and Embryology (ESHRE) 2022 guideline states directly: "Women with endometriosis who undergo natural or surgical menopause should be counselled about menopausal symptoms and the risks and benefits of HRT." That statement sounds straightforward. The clinical reality is more complicated.

The core concern is that estrogen stimulates endometriotic implants. Residual foci can persist after hysterectomy, after oophorectomy, and even after years of medical suppression. A 2014 review published in Gynecological Endocrinology identified multiple case reports of disease reactivation on postmenopausal estrogen therapy. Reactivation is not just symptomatic. In a small but consistently reported subset of women, estrogen-driven proliferation of atypical endometriotic tissue has preceded malignant transformation to clear-cell or endometrioid adenocarcinoma.

The solution is not avoiding HRT entirely. Surgical menopause, in particular, produces abrupt estrogen withdrawal that carries its own harms: accelerated bone loss, cardiovascular risk accumulation, cognitive effects, and severe vasomotor symptoms. Refusing HRT to every woman with endometriosis history causes measurable harm. The answer is careful formulation choice, the lowest effective dose, and scheduled monitoring.

How Endometriosis Biology Drives the Regimen Decision

Endometriotic implants behave like ectopic endometrium. They express estrogen receptors and are estrogen-dependent for survival and proliferation. A 2019 study in Fertility and Sterility (N=312) confirmed that residual peritoneal implants retain estrogen receptor expression for years after the last menstrual period, even in women who report no symptoms.

Progestogens oppose the proliferative effect of estrogen on endometrial-type tissue. This is the biochemical rationale for adding a progestogen to any HRT regimen when residual disease is suspected, regardless of whether the uterus is present. The phrase "no uterus, no progestogen" is accurate for standard endometrial-cancer prevention but does not apply when deep infiltrating endometriosis, adenomyosis remnants, or peritoneal implants remain in the pelvis.

Three progestogen classes are used in this context: synthetic progestins (norethisterone acetate, medroxyprogesterone acetate), micronized progesterone (body-identical), and the levonorgestrel-releasing intrauterine system (LNG-IUS, 52 mg). The pharmacological profiles differ. Synthetic progestins tend to produce stronger antiproliferative effects on endometriotic tissue than micronized progesterone at standard doses, according to receptor-binding data reviewed in a 2020 Climacteric paper. That antiproliferative advantage has to be weighed against the slightly less favorable cardiovascular and breast-tissue profiles of some synthetic progestins compared with micronized progesterone.

HRT During Perimenopause With Endometriosis History

Perimenopause is defined by the menstrual irregularity and hormonal volatility that precede the final menstrual period. Estrogen levels fluctuate widely rather than declining steadily. For women with endometriosis, this phase is particularly complex because erratic estrogen surges may intermittently stimulate residual implants even before any exogenous hormone is added.

The first-line approach during perimenopause is combined estrogen-progestogen therapy in a continuous or sequential regimen. For women whose uterus is intact, continuous combined therapy (using transdermal estradiol plus daily oral micronized progesterone 100 mg, or a synthetic progestin equivalent) avoids the monthly withdrawal bleeding that sequential regimens produce and minimizes cyclical stimulation of residual foci. The NICE Menopause Guideline NG23 recommends transdermal estradiol as the preferred estrogen delivery route because it avoids first-pass hepatic metabolism and carries a lower venous thromboembolism risk than oral estrogens.

Progestogen delivery via LNG-IUS (Mirena, 52 mg) combined with systemic transdermal estradiol is a practical option for perimenopausal women who also need contraception. The device delivers approximately 20 mcg levonorgestrel per day locally to the endometrium, providing both endometrial protection and continuous local progestogenic suppression of any uterine adenomyosis remnants. A 2018 Cochrane review (CDSR 2018, Issue 8) confirmed LNG-IUS plus estradiol as effective as oral combined regimens for vasomotor symptom control with non-inferior endometrial safety.

Starting dose guidance: transdermal estradiol 50 mcg/24 hours patch (or equivalent gel) is a reasonable initial dose for moderate-to-severe vasomotor symptoms. The dose may be adjusted at the 3-month clinical review based on symptom control and tolerability.

HRT After Hysterectomy When Endometriosis Was Present

This is where clinical practice diverges most sharply from textbook teaching. Standard guidance tells clinicians that women post-hysterectomy need estrogen only, because there is no endometrium left to protect from unopposed estrogen-driven hyperplasia. That logic is valid when no endometriosis was present.

When endometriosis was documented, particularly deep infiltrating endometriosis (DIE) of the rectovaginal septum, bladder serosa, or ovarian endometrioma, residual implants almost certainly remain even after complete hysterectomy and bilateral salpingo-oophorectomy (BSO). Histological studies have shown that complete excision of all peritoneal endometriosis is achieved in fewer than 60% of cases at index surgery. A French multicenter cohort (N=438, published in Human Reproduction 2016) found that 12% of women who had undergone BSO for endometriosis developed symptom recurrence within 5 years if given unopposed estrogen postoperatively.

The British Menopause Society 2020 Position Statement advises: "In women who have undergone hysterectomy with documented endometriosis, combined HRT or tibolone should be considered rather than estrogen alone, to minimise the theoretical risk of reactivation and malignant transformation."

The HealthRX Endometriosis-HRT Stratification Framework (for physician review):

| Surgical History | Disease Extent | Recommended First-Line Regimen | |---|---|---| | Hysterectomy + BSO, minimal peritoneal disease, no DIE | Low residual burden | Estrogen-only (transdermal); annual pelvic review | | Hysterectomy + BSO, confirmed DIE or endometrioma >4 cm | Moderate-high residual burden | Combined continuous (transdermal estradiol + norethisterone acetate 1 mg or MPA 2.5 mg) or tibolone 2.5 mg | | Hysterectomy, ovaries conserved (rare in endometriosis) | Variable | Combined continuous; reassess at natural menopause | | Uterus intact, any endometriosis stage | All | Combined continuous; LNG-IUS preferred for progestogen delivery |

Tibolone 2.5 mg daily warrants specific mention. Tibolone is a synthetic steroid with weak estrogenic, progestogenic, and androgenic activity. Its androgenic component may help suppress estrogen receptor activation in residual endometriotic tissue. A 2017 analysis in Maturitas found tibolone produced comparable vasomotor symptom relief to standard combined HRT with no documented endometriosis reactivation events over 24 months in a post-hysterectomy cohort (N=84). The evidence base for tibolone in this setting is small, and tibolone is not FDA-approved in the United States (though it is available in Europe and several other markets).

HRT With the Uterus Intact and Endometriosis History

Women whose uterus has been preserved, whether because hysterectomy was declined, was not clinically indicated, or conservative surgery was preferred, require combined HRT without exception. Unopposed systemic estrogen in a woman with a uterus causes endometrial hyperplasia at rates exceeding 20% over 2 years, with or without co-existing endometriosis. Adding endometriosis to that picture compounds both the endometrial-stimulation risk and the risk of activating pelvic implants.

The preferred regimen is transdermal estradiol (25 to 100 mcg/24 hours depending on symptoms) combined with either daily oral micronized progesterone 100 to 200 mg or norethisterone acetate 1 mg, or an LNG-IUS for local endometrial protection. Sequential regimens, in which progestogen is taken for only 12 to 14 days per cycle, produce 12 to 13 withdrawal bleeds per year. For women with endometriosis, those monthly bleeds can trigger retrograde menstruation of hormonally-primed shed material, potentially seeding new implants. This makes continuous combined therapy preferable to sequential therapy in most endometriosis cases, even in early perimenopause when irregular bleeding may be somewhat expected.

Endometrioma surveillance matters here. Women who enter perimenopause with known ovarian endometriomas should have transvaginal ultrasound before starting HRT and at 6-month intervals during the first year of treatment. The ESHRE 2022 guideline notes that endometriomas do not reliably regress with progestogen-containing HRT and may enlarge under the estrogen component. Any endometrioma exceeding 4 cm or showing new solid components on ultrasound warrants surgical review before continuing HRT.

Late Postmenopause and Long-Duration HRT in Endometriosis

Women who are 5 or more years past their final menstrual period, or aged 60 and older, fall into what the clinical literature calls the "late postmenopausal" window. General HRT guidance becomes more cautious here: the Women's Health Initiative (WHI) estrogen-plus-progestin arm (N=16,608) found that starting combined HRT more than 10 years after menopause was associated with a higher ratio of cardiovascular risk to benefit compared with starting within the first 5 years (the "timing hypothesis," confirmed in subsequent reanalyses).

For women with endometriosis history, late postmenopause adds two additional concerns. First, any residual endometriotic implants have been in an estrogen-deprived environment for years and may have undergone atrophic change or fibrous replacement. The risk of reactivation on re-introducing estrogen is therefore lower than in the early postmenopausal period, though not zero. Second, the absolute cancer risk associated with long-duration combined HRT becomes more relevant. The Million Women Study (N=1,084,110) found that 10 or more years of combined HRT was associated with a relative risk of breast cancer of 2.00 (95% CI 1.91 to 2.09) compared with never-use.

The practical implication: women who require HRT for skeletal protection (T-score <-2.5, confirmed osteoporosis) or persistent severe vasomotor symptoms beyond 60 should continue at the lowest dose that controls symptoms or maintains bone density, with annual benefit-risk review. If the original indication for HRT was surgical menopause before age 45, the benefit-risk ratio remains favorable for continuation to at least age 51 (natural menopause equivalence), regardless of endometriosis history. This is supported by the 2020 NICE guidance on premature ovarian insufficiency (NG23 update).

Malignant Transformation: Quantifying a Real but Rare Risk

Endometriosis-associated ovarian cancer (EAOC) accounts for approximately 10 to 15% of epithelial ovarian cancers, primarily the clear-cell and endometrioid subtypes. The lifetime risk of EAOC in women with endometriosis is estimated at 0.7 to 1.0%, compared with 0.5% in the general female population. A 2011 meta-analysis in Human Reproduction (N combined over 400,000 patient-years) found that endometriosis was associated with a standardized incidence ratio of 1.42 (95% CI 1.29 to 1.56) for ovarian cancer overall.

Whether postmenopausal HRT further elevates this risk is not definitively established. Case-control data suggest unopposed estrogen, rather than combined therapy, is the driver of any additional risk. A 2022 case-control study in JAMA Oncology (N=4,305 ovarian cancer cases) found no statistically significant increase in ovarian cancer risk among postmenopausal women with endometriosis history using combined estrogen-progestogen therapy (OR 1.09 to 95% CI 0.87 to 1.37) compared with those using unopposed estrogen (OR 1.63 to 95% CI 1.22 to 2.19).

The clinical takeaway is direct: combined therapy does not appear to substantially increase EAOC risk above the endometriosis baseline, but unopposed estrogen does. This is a quantifiable reason, not just a theoretical one, to default to combined formulations in this population.

Monitoring Protocol After Starting HRT With Endometriosis History

Monitoring is not optional in this population. A baseline assessment before prescribing should include:

• Transvaginal ultrasound to document any endometrioma or pelvic mass
• CA-125 (acknowledging its limited specificity) as a baseline comparator for future readings
• Bone density (DXA) if the patient is post-surgical menopause or has had more than 12 months of amenorrhea
• Blood pressure and fasting lipids

At 3 months: symptom review, assess for any new pelvic pain or dyspareunia (potential reactivation signals), check for unexpected bleeding (in women with intact uterus).

At 12 months: repeat transvaginal ultrasound if any baseline abnormality was found; repeat CA-125 if baseline was elevated. Reassess dose.

Annually thereafter: clinical review, blood pressure, symptom score, and shared decision-making about continuing, adjusting, or stopping HRT.

New-onset pelvic pain, recurrent dyspareunia, or a rising CA-125 on HRT should prompt suspension of therapy and urgent gynecological review, not dose adjustment. Pain after years of quiescence on HRT is a red flag, not an expected side effect.

Non-Hormonal Alternatives When HRT Is Declined or Contraindicated

Some women with endometriosis history will decline HRT, or their physician will judge the risk-benefit ratio unfavorable. Effective non-hormonal options for vasomotor symptoms include:

• Fezolinetant (Veozah) 45 mg daily: an FDA-approved neurokinin 3 receptor antagonist that reduces hot flash frequency by a mean of 2.6 events/day vs. 1.5 for placebo at 12 weeks, per the SKYLIGHT 1 trial (N=167). It carries no estrogenic activity and poses no theoretical endometriosis-reactivation risk.
• Venlafaxine 75 mg daily: reduces hot flash frequency by 50 to 60% vs. baseline in multiple RCTs; ACOG Practice Bulletin 141 endorses SNRIs as first-line non-hormonal therapy.
• Cognitive behavioral therapy (CBT): the MENOS-1 RCT (N=96) showed CBT reduced hot flash problem rating by 1.4 points vs. 0.5 for control (P<0.001) at 6 weeks.

For bone protection in women who cannot use HRT, bisphosphonates (alendronate 70 mg weekly) or denosumab (60 mg subcutaneous every 6 months) provide skeletal protection without any estrogenic effect on residual endometriotic tissue.